Is Macerich a Good REIT to Own?

NYSE: MAC | Macerich Co. News, Ratings, and Charts

MAC – Real estate investment trust (REIT) Macerich’s (MAC) has been ramping up its efforts to move past pandemic disruptions and reported significant improvement in its last quarter, with robust leasing demand and tenant sales. However, MAC’s shares have plunged more than 30% in price this year. And considering bearish analysts’ sentiments around the stock, the question is, is MAC a buy now? Keep reading to learn our view.

Fully integrated and self-managed real estate investment trust (REIT) The Macerich Company (MAC) in Santa Monica, Calif., focuses on the acquisition, leasing, management, development, and redevelopment of regional malls throughout the United States. The company currently owns 48 million square feet of real estate, which consists primarily of interests in 44 regional town centers. Also, MAC announced it would welcome 17 Cotton On Group stores to regional town centers across the U.S., adding to the 12 stores already open within Macerich’s portfolio.

MAC is rebounding from the COVID-19 pandemic hit, with people returning to in-person experiences and mall visits since last year with easing of restrictions and increasing consumer demand and spending. In the first quarter, ended March 31, 2022, MAC’s portfolio comparable tenant sales from spaces less than 10,000 were 14.5% higher than the first quarter of 2021 and 11.5% higher than the first quarter of 2019. Its portfolio tenant sales per square foot for spaces less than 10,000 square feet for the trailing 12 months, ended March 31, 2022, were a record high of $843. Also, during the quarter, MAC signed 22% more leases than it signed during the first quarter of 2021. Furthermore, its same-center net operating income (NOI), excluding lease termination income, increased 24.7% year-over-year. However, the company’s bottom line is still in the red.

MAC shares have slumped 23.7% in price over the past year and 33.9% year-to-date to close the last trading session at $11.43. It is currently trading below its 50-day and 200-day moving averages.

Here is what could shape MAC’s performance in the near term:

Mixed Growth Story

MAC’s revenues have declined at a 5.3% CAGR over the past three years, while its EBITDA has declined at a 10.1% CAGR over the past three years. And its net income and EPS have declined at CAGRs of 26.3% and 35.8%, respectively,  over the past three years.

For its fiscal first quarter ended March 31, 2022, the company’s total revenues increased 13.5% year-over-year to $216.14 million. Its FFO came in at $104.87 million, reflecting an increase of 43.6% from its  year-ago value, while its FFO per share rose 9.3% year-over-year to $0.47. Its net loss attributable to the company was $37.18 million or $0.17 per share during the first quarter of 2022, compared to $63.60 million or $0.40 per share in the prior-year quarter.

Mixed Profitability

MAC’s 38.51% forward AFFO ratio  is 47% lower than the 72.64% industry average. Also, its 30.96% forward FFO payout ratio is 52.6% lower than the 65.29% industry average, while its 42.40% trailing-12-month cash dividend payout ratio  is 33.9% lower than the 64.31% industry average. Furthermore, its trailing-12-month gross profit margin and net income margin are 17.8% and 74.9% lower than the industry averages, respectively.

However, its 42.46% trailing-12-month levered FCF margin compares with the 37.61% industry average. Also, its 18.73% trailing-12-month dividend yield to FAD payout ratio compares with the 5.90% industry average.

Bearish Analysts Sentiments

Analysts expect the company’s revenues to decrease 7.8% year-over-year in the current quarter, ending June 30, 2022, to $198.58 million. Also, its revenues are expected to decline 4% in the next quarter, ending Sept. 30, r 2022, and 3.3% in the quarter ending Dec. 31, 2022. The company’s revenue is expected to increase 1.6% year-over-year in the current year. And  the consensus FFO per share estimate of $1.96 for the fiscal year ending Dec. 31, 2022, indicates a 3.6% year-over-year decline. Moreover, MAC’s FFO per share is expected to decline  23.1% in the current  quarter. In addition, the Street expects the company’s EPS to decline 157.1% in the current  year. And its EPS is expected to remain negative for at least this year.

Furthermore, among the seven Wall Street analysts that have rated the stock, five have rated it Sell, one rated it Hold, and one rated it Buy.

POWR Ratings Reflect Uncertain Prospects

MAC has an overall C rating, which translates to Neutral in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

The stock has a grade of C for Quality, which is consistent with its mixed profitability.

MAC has an F grade for Sentiment. Bearish analyst sentiment about the stock justifies this grade.

Among  the 32 stocks in the D-rated REITs – Retail industry, MAC is ranked #27.

Beyond what I have stated above, one can also view MAC’s grades for Value, Growth, Momentum, and Stability here.

View the top-rated stocks in the REITs – Retail industry here.

Bottom Line

Although REITs typically tend to be attractive to income investors due to their reliable dividend payouts, MAC’s dividend payouts have declined at a 41.4% CAGR over the past three years and 26.4% over the past five years. Furthermore, it has an extremely high dividend payout ratio of 315.8%, which questions the sustainability of its dividend payment. The company has demonstrated a significant rebound in its last reported quarter, but I think it could be wise to wait for further improvement in its financial positioning before investing in the stock.

How Does the Macerich Company (MAC) Stack Up Against its Peers?

While MAC has an overall POWR Rating of C, one  might want to consider taking a look at its industry peers, Saul Centers, Inc. (BFS), SmartCentres Real Estate Investment Trust (CWYUF), and RioCan Real Estate Investment Trust (RIOCF), which have a B (Buy) rating.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year

Top 10 Stocks for 2022

Bear Market Scare? Read Before Your Next Trade

7 SEVERELY Undervalued Stocks


MAC shares were unchanged in premarket trading Wednesday. Year-to-date, MAC has declined -32.42%, versus a -17.06% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MACGet RatingGet RatingGet Rating
BFSGet RatingGet RatingGet Rating
CWYUFGet RatingGet RatingGet Rating
RIOCFGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Macerich Co. (MAC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MAC News